Top

Cancer Causes & Control

Published in:

01-12-2013 | Original paper

Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer

Authors: M. T. Faber, A. Jensen, K. Frederiksen, E. Glud, E. Høgdall, C. Høgdall, J. Blaakær, S. K. Kjær

Published in: Cancer Causes & Control | Issue 12/2013

Abstract

Purpose

Oral contraceptive use decreases the risk of ovarian cancer, but no previous studies have assessed the impact of cumulative intake of estrogen and progestin on ovarian cancer risk.

Methods

We used data from a population-based case–control study conducted in Denmark in 1995–1999 among women aged 35–79 years; 554 women with epithelial ovarian cancer and 1,564 age-matched controls were included in the analyses. Data were analyzed in multiple logistic regression models.

Results

The use of combined oral contraceptives only and the mixed use of combined and progestin-only pills decreased the risk of ovarian cancer, while no association was found with exclusive use of progestin-only pills. No major differences in risk were found for users of combined oral contraceptives with high- and low-potency estrogen and progestin. There was no effect of cumulative progestin intake, but decreased risks of ovarian cancer with increasing cumulative intake of estrogen (OR = 0.82; 95 % CI 0.67–0.99, per 100 mg estrogen) and increasing duration of oral contraceptive use (OR = 0.95; 95 % CI 0.92–0.98, per year of use) were found. No effect of cumulative estrogen intake was found, however, after adjustment for duration of oral contraceptive use.

Conclusions

The protective effect of oral contraceptives against ovarian cancer may be sufficiently explained by duration of anovulation. This suggests that if the estrogen and progestin doses are sufficient to cause anovulation, a higher intake of estrogen or progestin confers no extra protection against ovarian cancer.

Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–314PubMedCrossRef

Søgaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakær J et al (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarks Prev 16(6):1160–1166CrossRef

Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163PubMedCrossRef

Konishi I (2006) Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int J Gynecol Cancer 16(1):16–22PubMedCrossRef

Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786PubMedCrossRef

Ivarsson K, Sundfeldt K, Brannstrom M, Janson PO (2001) Production of steroids by human ovarian surface epithelial cells in culture: possible role of progesterone as growth inhibitor. Gynecol Oncol 82(1):116–121PubMedCrossRef

Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS et al (1998) Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5(5):271–276PubMedCrossRef

Wilson NM, Laursen M, Lidegaard O (2012) Oral contraception in Denmark 1998–2010. Acta Obstet Gynecol Scand 91(7):810–815PubMedCrossRef

Ness RB, Grisso JA, Klapper J, Schlesselman JJ, Silberzweig S, Vergona R et al (2000) Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid hormones and reproductions. Am J Epidemiol 152(3):233–241PubMedCrossRef

10.

Rosenblatt KA, Thomas DB, Noonan EA (1992) High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO collaborative study of neoplasia and steroid contraceptives. Eur J Cancer 28A(11):1872–1876PubMedCrossRef

11.

Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL et al (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7):654–661PubMed

12.

Royar J, Becher H, Chang-Claude J (2001) Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 95(6):370–374PubMedCrossRef

13.

Sanderson M, Williams MA, Weiss NS, Hendrix NW, Chauhan SP (2000) Oral contraceptives and epithelial ovarian cancer. Does dose matter? J Reprod Med 45(9):720–726PubMed

14.

Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH (2004) Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril 82(1):186–195PubMedCrossRef

15.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94(1):32–38PubMedCrossRef

16.

Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT (2007) Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 109(3):597–607PubMedCrossRef

17.

Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E et al (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164(20):2253–2259PubMedCrossRef

18.

Bolt HM, Bolt WH (1974) Pharmacokinetics of mestranol in man in relation to its oestrogenic activity. Eur J Clin Pharmacol 7(4):295–305PubMedCrossRef

19.

Dickey RP, Stone SC (1976) Progestational potency of oral contraceptives. Obstet Gynecol 47(1):106–112PubMed

20.

Hahn DW, Allen GO, McGuire JL (1977) The pharmacological profile of norgestimate. A new orally active progestin. Contraception 16(5):541–553PubMedCrossRef

21.

Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E (2004) Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Br J Cancer 90(7):1386–1391PubMedCrossRef

22.

Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF et al (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189PubMedCrossRef

23.

Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO et al (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16(6):631–650PubMedCrossRef

24.

Rivera R, Yacobson I, Grimes D (1999) The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 181(5 Pt 1):1263–1269PubMedCrossRef

25.

Rang HP, Dale MM, Ritter JM (1999) The reproductive system. In: pharmacology, 4th edn. Churchill Livingstone, Edinburgh, pp. 436–53

26.

Kiley J, Hammond C (2007) Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 50(4):868–877PubMedCrossRef

27.

Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860–864PubMedCrossRef

28.

Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373PubMedCrossRef

29.

Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363–372PubMedCrossRef

30.

Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA et al (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131(4):938–948PubMedCrossRef

31.

Kurian AW, Balise RR, McGuire V, Whittemore AS (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96(2):520–530PubMedCrossRef

32.

Modugno F, Ness RB, Wheeler JE (2001) Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 11(8):568–574PubMedCrossRef

33.

Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638PubMedCrossRef

34.

Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 343:d6423. doi:10.1136/bmj.d6423 PubMedCrossRef

35.

Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335(7621):651–659PubMedCrossRef

Title: Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer
Authors: M. T. Faber
A. Jensen
K. Frederiksen
E. Glud
E. Høgdall
C. Høgdall
J. Blaakær
S. K. Kjær
Publication date: 01-12-2013
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 12/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-013-0296-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2013

Eating frequency and risk of colorectal cancer

Erratum to: Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in Norway

Fruit and vegetable intake and breast cancer risk defined by estrogen and progesterone receptor status: the Japan Public Health Center-based Prospective Study

Circulating leptin levels and risk of colorectal cancer and adenoma: a case–control study and meta-analysis

Other considerations about carcinogenicity of sulfur mustard

Lifetime body size and prostate cancer risk in a population-based case–control study in Sweden

Keynote webinar | Spotlight on antibody–drug conjugates in cancer